

Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study

Frederik van Gemert, Bruce Kirenga, Niels Chavannes, Moses Kamywa, Simon Luzige, Patrick Musinguzi, John Turyagaruka, Rupert Jones, Ioanna Tsiligianni, Sian Williams, Corina de Jong, Thys van der Molen



Summary

Background In sub-Saharan Africa, little is known about the damage to respiratory health caused by biomass smoke and tobacco smoke. We assessed the prevalence of chronic obstructive pulmonary disease (COPD) and related risk factors in a rural region of Uganda.

Methods We did this prospective observational cross-sectional study in rural Masindi, Uganda. We randomly selected people above the age of 30 years from 30 villages. Trained local health-care workers asked validated questionnaires and administered spirometry to participants. We defined COPD as FEV₁/FVC less than the lower limit of normal. We calculated prevalence of COPD and tested its association with risk factors.

Findings Between April 13, and Aug 14, 2012, we invited 620 people to participate, of whom 588 provided acceptable spirometry and were analysed. Mean age was 45 years (SD 13·7); 297 (51%) were women. 546 (93%) were exposed to biomass smoke. The prevalence of COPD was 16·2% (15·4% in men, 16·8% in women). Prevalence was highest in people aged 30–39 years (17 [38%] of 45 men, 20 [40%] of 50 women). 20 (44%) of 45 men with COPD were current smokers (mean age 40 years, SD 7·5), 11 (24%) were former smokers (mean age 49 years, SD 11·0); four [8%] of 50 women were current smokers (mean age 52 years, SD 18·1), nine (18%) were former smokers (mean age 64 years, SD 16·2). Mean Clinical COPD Questionnaire score was 0·81 (SD 0·78), mean Medical Research Council dyspnoea score was 1·33 (SD 0·65); 28 (30%) of 95 patients had had one or more exacerbations past 12 months. COPD was associated with wheeze (odds ratio 2·17, 95% CI 1·09–4·34; $p=0\cdot028$) and being a former smoker (1·96, 1·07–3·59; $p=0\cdot029$).

Interpretation In this rural district of Uganda, COPD starts early in life. Major risk factors were biomass smoke for both sexes and tobacco smoke for men. In addition to high smoking prevalence in men, biomass smoke could be a major health threat to men and women in rural areas of Uganda.

Funding International Primary Care Respiratory Group.

Copyright © van Gemert et al. Open Access article distributed under the terms of CC BY.

Introduction

Non-communicable diseases have often been considered less important than communicable diseases in low-income and middle-income countries.¹ However, chronic obstructive pulmonary disease (COPD), once regarded as a disease of high-income countries, is now recognised as common in low-income and middle-income countries.^{2,3} COPD is the fourth leading cause of death worldwide, and is predicted to become the third by 2020, surpassing the combined mortality for malaria, tuberculosis, and HIV/AIDS in Africa.^{4–6}

The main causes of COPD in high-income countries are tobacco smoke and occupational exposure, but in low-income and middle-income countries use of biomass fuel (wood, dung, crop residues, and charcoal) for cooking and domestic heating is also a major cause of COPD and childhood respiratory infections.^{2,7–9} Biomass fuels are often burned inefficiently in open fires, leading to high levels of indoor air pollution, exceeding health

limits specified by international standards of ambient air quality.⁷ Worldwide, biomass fuels are used in about 50% of households, exposing more than 3 billion people to their adverse effects.^{9,10} Other contributing risk factors for COPD in low-income and middle-income countries are a history of tuberculosis, untreated asthma, respiratory infections, kerosene-based lighting, and socioeconomic factors such as malnutrition and poverty.⁵

In sub-Saharan Africa, particularly in rural regions, knowledge of COPD is very poor; many people (health-care workers, government officials, and the public) are unaware of the damage to respiratory health caused by tobacco and biomass fuel smoke.¹¹ Data for the burden of COPD and related risk factors are scarce or not available. Some surveys have been done in Africa;¹² however, they have often been of poor quality—for example, COPD diagnosis based on the presence of symptoms rather than spirometry or bronchodilator use.^{10,12} Only two population studies have used appropriate methods and population-

Lancet Glob Health 2015;
3: e44–51

See [Comment](#) page e6

University of Groningen,
University Medical Centre
Groningen, Harlingen,
Netherlands (F van Gemert MD,
I Tsiligianni PhD, C de Jong PhD,
Prof T van der Molen PhD);
Makerere University, Mulago
Hospital, Kampala, Uganda
(B Kirenga MMed,
Prof M Kamywa PhD,
S Luzige MMed,
P Musinguzi MMed); Leiden
University Medical Centre,
Leiden, Netherlands
(N Chavannes PhD); District
Health Office, Masindi, Uganda
(J Turyagaruka MPH); Peninsula
Medical School, University of
Plymouth, Plymouth, UK
(R Jones MD); and International
Primary Care Respiratory
Group, Edinburgh, UK
(S Williams MSc)

Correspondence to:
Frederik van Gemert,
Department of General Practice,
University of Groningen,
University Medical Centre
Groningen, PO Box 196,
9700 AD Groningen,
Netherlands
frgemert@xs4all.nl

See Online for appendix

representative sampling. In 2007, the Burden of Lung Disease study¹³ in South Africa showed a high prevalence of stage 2 or higher COPD (22·2% in men and 16·7% in women) in an urban population older than age 40 years, associated with previous tuberculosis and occupational exposure in addition to smoking. In 2008–09, a survey done in urban and rural Rwanda reported a COPD prevalence of 9·6% in people older than age 45 years.¹⁴

We did a study (FRESH AIR Uganda) to assess the prevalence and burden of COPD and related risk factors in adults in a poor rural region of Uganda.

Methods

Study design and participants

We did this population-based, observational, cross-sectional study between April 13, and Aug 14, 2012, in the rural district of Masindi (population 350 000) in Uganda, a low-income country with an average life expectancy of 52 years (48 years for men, 57 years for women).¹⁵ 25 local nurses and health officers were recruited as research assistants and received a 5-day training course in high-quality spirometry.¹⁶

We chose Masindi district because it had a stable population in a defined rural area and a functional health system. In collaboration with the National Bureau of Statistics in Uganda, we selected 30 villages with a probability proportional to their size. Each village contained an estimated 150 households; each household consisted of 1·5 adults on average. Selected villages were visited to count the households. In each village, 20 households were then selected, with simple random sampling using R statistical software. From the chosen households all eligible men and women were invited to participate.

Exclusion criteria were age younger than 30 years, history of any mental illnesses; myocardial infarction in the past 6 weeks; hospital admission for cardiac illnesses within the past 6 months; thoracic, abdominal, or eye surgery (or retinal detachment) in the past 6 weeks; active tuberculosis; pregnancy; and present lung infection (participants were included after recovery). Age 30 years was chosen as the cutoff to avoid missing people with premature airflow obstruction because exposure to biomass smoke starts during early childhood.^{6–11}

The liaison officer from the district health office visited the villages and, together with the village leader, explained the purpose of the survey to eligible participants. Each participant signed an informed consent form, or in case of illiteracy, thumb-printed and signed by a witness. The study was approved by the Makerere University School of Medicine Research and Ethics Committee and the Uganda National Council for Science and Technology.

Procedures

Weight and height were measured. A screening questionnaire, developed from different validated questionnaires and adapted to local circumstances, was

completed during a face-to-face interview (appendix).^{17–19} The questions included tribal origin, education, occupation, living in tobacco-growing areas, respiratory symptoms (cough, sputum, wheezing, shortness of breath), Medical Research Council dyspnoea scale score, chest infections, tobacco use, biomass fuel use, cooking and sleeping areas, tuberculosis, comorbidities, drug treatments, admission to hospital, and visits to health centres.

All participants underwent spirometry after explanation by a research assistant in their local language. Spirometry was done in accordance with the American Thoracic Society and European Respiratory Society recommendations: at least three acceptable and reproducible blows with the largest and second-largest values for both forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV₁) within 150 mL or no more than 5% difference; the largest values for FVC and FEV₁ were considered the best and used for analysis.^{6,16} Spirometry was done while seated, using Pneumotrac with Spirotrac V software (version 1.06). A new filter was applied for each measurement to avoid contamination. Spirometers were calibrated every morning with a 1 L syringe and weekly with a biological control.

In most epidemiological surveys, COPD is defined by spirometry and few clinical characteristics.²⁰ This contrasts with clinical guidance recommending a diagnosis based on compatible spirometry and clinician's assessment of exposure to risk factors, symptoms, limitations, health-related quality-of-life, and exacerbations.^{6,16}

We used a pre-bronchodilator FEV₁:FVC ratio of less than 0·8 or an FVC of less than 80% as cutoffs for whether or not to do a post-bronchodilator assessment, to avoid underestimating FVC, which could result in a normal FEV₁:FVC ratio.²¹ Participants took a short-acting bronchodilator (salbutamol 200 µg) administered with a Redihaler (to avoid possible infections with a spacer) and spirometry was repeated 15 min thereafter. All spirometry results were reviewed weekly by the investigators; those which did not meet the quality criteria were repeated.

The Global Initiative for Chronic Obstructive Lung Disease definition of airflow obstruction includes a fixed FEV₁:FVC ratio of less than 0·7 after administration of an inhaled bronchodilator.⁶ Because this definition could lead to over-diagnosis in elderly participants and under-diagnosis in young participants, we used a lower limit of normal threshold to define COPD—ie, participants below the fifth percentile of the predicted FEV₁:FVC ratio (calculated with GLI2012 DataConversion software; version 3.3.1).^{22–24} Classification of severity of COPD was based on the Global Initiative for Chronic Obstructive Lung Disease criteria: mild obstruction, FEV₁ ≥80%; moderate obstruction, FEV₁ 50–79%; severe obstruction, FEV₁ 30–49%; and very severe obstruction, FEV₁ <30%.^{6,20}

We assessed health-related quality-of-life with the Clinical COPD Questionnaire, a ten-item questionnaire divided into three domains (symptoms, mental state, and functional state) and translated to the main local languages.²⁵ The final mean score of the Questionnaire was calculated, with a higher score representing worse health status.^{6,20}

Statistical analysis

The intended sample size was 600 participants, calculated to give an acceptable degree of reliability for estimating prevalence (for an estimate prevalence of 15%, 95% CI 12.1–17.9).¹³ We compared COPD prevalence in men and women with a χ^2 test. We did univariate analyses to evaluate associations between COPD and possible risk factors, selected on basis of previously studies.^{2,3,6} For normally distributed variables we used Student's *t* tests and Pearson correlation coefficient, and for non-normally distributed variables we used Mann-Whitney *U* tests and Spearman's correlation coefficient. The risk factors were age, sex, occupation, wheeze, cough, shortness of breath, smoking status, pack years, time cooking indoors, time cooking outdoors, respiratory infections, asthma, heart failure, tuberculosis, and socioeconomic factors. We included risk factors that had a *p* value lower than 0.2 in the univariate analyses in subsequent multivariate regression analysis using the backward Wald method.²⁶ Selection of the logistic models was based on Nagelkerke's *R*², Hosmer-Lemeshow test, and the receiver operating characteristic curve. We considered *p* values less than 0.05 as statistically significant and *p* values of 0.05–0.1 as trends. We did the statistical analysis with SPSS (version 20).

Role of the funding source

The funder of the survey had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data and had final responsibility for the decision to submit for publication.

Results

Of the 620 people invited to participate, 609 underwent spirometry (figure 1). 588 (97%) of 609 people (291 men and 297 women) provided acceptable spirometry (figure 1). We detected no statistically significant differences between the 588 people with acceptable spirometry and the 21 people without acceptable spirometry in terms of age, sex, smoking behaviour, and tuberculosis infection (data not shown). Mean age was 45.2 years (SD 13.6); 414 (70%) participants were aged 30–49 years. 485 (83%) lived in rural areas and 440 (75%) were farmers. Electricity was not available for 545 (93%) participants; 552 (94%) used kerosene-based lighting.

Almost all participants, both men and women, were exposed to biomass smoke, indoor as well as outdoor

(table 1). In 521 (98%) of 546 exposed participants, wood was the main solid fuel for cooking, used in an open fire. Smoking was more common in men than in women (table 1), particularly among young men: 52 (52%) of 100 male smokers were younger than 39 years (data not shown).

According to the definition of COPD as $FEV_1:FVC$ less than the lower limit of normal, the prevalence of COPD




Figure 1: Study participants

	Men (n=291)	Women (n=297)
Age (years)	45.0 (12.8)	45.4 (14.5)
Body-mass index (kg/m ²)	22.2 (3.2)	23.7 (4.9)
Education		
None	25 (8.6%)	93 (31.3%)
Primary (age 7–13 years)	189 (64.9%)	169 (56.9%)
Secondary (age 13–19 years)	63 (21.6%)	28 (9.4%)
Tertiary (age >19 years)	14 (4.8%)	7 (2.4%)
Smoking status		
Current smoker	100 (34.4%)	22 (7.4%)
Former smoker	63 (21.6%)	24 (8.1%)
Never smoker	128 (44.0%)	251 (84.5%)
Biomass fuel use		
Indoor exposure	265 (91.1%)	281 (94.6%)
Hours exposed per day	3.1 (2.5)	5.2 (2.4)
Years exposed	25.5 (18.4)	33.3 (18.2)
Outdoor exposure	262 (90.0%)	282 (94.9%)
Hours exposed per day	1.3 (1.7)	1.9 (2.5)
Years exposed	20.3 (16.9)	25.5 (17.7)

Data are mean (SD) or number (%).

Table 1: Demographic characteristics of study population




Figure 2: Age of participants with chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease defined as ratio of forced expiratory volume in 1 s to forced vital capacity less than the lower limit of normal.

was 16.2% (95 of 588 participants); 50 (52.6%) were women. The mean age of patients with COPD was 46.7 years (SD 14.0). Among participants with COPD, 17 (38%) of 45 men and 20 (40%) of 50 women were aged 30–39 years; seven (7.4%) were older than 70 years (figure 2). Most participants had mild airflow obstruction, a fifth had moderate obstruction, and few had severe obstruction; no participants had very severe obstruction (table 2). 12 (2%) of 588 participants had asthma and eight (1.4%) had a restrictive spirometry pattern. Almost all patients had never had tuberculosis; 5% did not know (table 3). 27 (4.6%) of 588 participants reported being HIV positive.

According to the Global Initiative for Chronic Obstructive Lung Disease criterion, COPD prevalence was 12.4% (73 of 588 participants); 32 (43.8%) were women. Mean age of COPD patients using this criterion was 55.5 years (SD 14.7); 11 (15.1%) were aged 30–39 years and 15 (20.5%) were older than 70 years (appendix).

Mean Clinical COPD Questionnaire score was 0.81 (SD 0.78); the mean score for the symptoms domain was 1.09 (SD 0.95), for the mental state domain it was 0.60 (SD 1.03), and for the functional state domain it was 0.64 (SD 0.88; table 2). The mean Medical Research Council dyspnoea score was 1.33 (SD 0.66)

	Men (n=45)	Women (n=50)
Symptoms		
Cough	15 (33.3%)	14 (28.0%)
Phlegm	13 (28.9%)	8 (16.0%)
Wheeze	9 (20.0%)	7 (14.0%)
Out of breath	4 (8.9%)	6 (12.0%)
MRC dyspnoea score	1.31 (0.70)	1.34 (0.63)
Clinical COPD Questionnaire score		
Total	0.76 (0.67)	0.85 (0.87)
Symptom	1.13 (0.84)	1.05 (1.05)
Mental	0.61 (1.10)	0.59 (0.97)
Functional	0.47 (0.60)	0.79 (1.05)
Exacerbations in the past 12 months		
0	32 (71.1%)	35 (70.0%)
1	2 (4.4%)	6 (12.0%)
2	4 (8.9%)	4 (8.0%)
3 or more	7 (15.6%)	5 (10.0%)
Spirometry*		
FVC (L)	4.03 (0.79)	2.91 (0.72)
FVC (% predicted)	116.4 (21.1)	116.8 (21.1)
FEV ₁ (L)	2.63 (0.59)	1.98 (0.64)
FEV ₁ (% predicted)	91.7 (17.2)	91.8 (20.3)
FEV ₁ :FVC	0.64 (0.07)	0.66 (0.06)
Severity in GOLD classification		
1 (mild)	37 (82.2%)	37 (74.0%)
2 (moderate)	7 (15.6%)	12 (24.0%)
3 (severe)	1 (2.2%)	1 (2.0%)
4 (very severe)	0	0

Data are n (%) or mean (SD). COPD=chronic obstructive pulmonary disease. GOLD=Global Initiative for Chronic Obstructive Lung Disease. MRC=Medical Research Council. FVC=forced vital capacity. FEV₁=forced expiratory volume in 1 s. *Post-bronchodilator.

Table 2: Clinical characteristics of participants with COPD (defined as FEV₁:FVC less than the lower limit of normal)

for participants with COPD, and 1.31 (SD 0.59) for participants without COPD. One or more exacerbations within the previous 12 months were reported by 28 (29.5%) of 95 participants with COPD, increasing with age (20% for people aged 30–39 years, 23% for people aged 40–49 years, 23% for people aged 50–59 years, 67% for those aged 60–69 years, and 57% for people aged >70 years). About a fifth of participants with COPD had two or more exacerbations in the past 12 months (table 3). The appendix shows the relation between airflow obstruction, cough, and dyspnoea score of 2 or more.

546 (92.9%) of 588 participants were exposed to indoor biomass smoke and 544 (92.5%) were exposed to outdoor biomass smoke. Univariate analysis showed that exposure did not differ significantly between COPD and non-COPD participants (table 3). The univariate analysis also showed that smoking status was associated with COPD (table 3). Cough and wheeze were significantly more common in patients with

	Non-COPD (n=493)		COPD (n=95)		p value (non-COPD vs COPD)		
	Men (n=246)	Women (247)	Men (n=45)	Women (n=50)	Men	Women	Both sexes
Smoking status					0.152	0.017	0.046
Current smoker	80 (32.5%)	18 (7.3%)	20 (44.4%)	4 (8.0%)	0.121	0.861	..
Former smoker	52 (21.1%)	15 (6.1%)	11 (24.4%)	9 (18.0%)	0.621	0.005	..
Never smoker	114 (46.3%)	214 (86.6%)	14 (31.1%)	37 (74.0%)	0.058	0.024	..
Indoor biomass fuel							
Participants exposed	225 (91.5%)	235 (95.1%)	40 (88.9%)	46 (92.0%)	0.578	0.370	0.335
Years exposed	26.1 (18.3)	32.9 (17.9)	22.0 (18.2)	36.2 (19.5)	0.168	0.241	0.965
Hours exposed per day	3.1 (2.6)	5.1 (2.6)	3.4 (2.1)	5.6 (2.6)	0.553	0.172	0.145
Outdoor biomass fuel							
Participants exposed	221 (89.8%)	236 (95.5%)	41 (91.1%)	46 (92.0%)	0.793	0.296	0.704
Years exposed	20.3 (17.0)	24.7 (17.5)	20.4 (16.1)	26.7 (18.6)	0.989	0.464	0.502
Hours exposed per day	1.2 (1.7)	1.9 (2.5)	1.6 (1.7)	2.0 (2.5)	0.380	0.939	0.143
Cooking area					0.117	0.297	0.711
Same building	44 (17.9%)	26 (14.6%)	8 (17.8%)	10 (20.0%)
Separate building	202 (82.1%)	221 (85.4%)	37 (82.2%)	40 (80.0%)
Village in tobacco-growing area	106 (43.1%)	91 (36.8%)	26 (57.8%)	18 (36.0%)	0.069	0.910	0.249
Chest infections					0.007	0.541	0.266
None	30 (12.2%)	20 (8.1%)	4 (8.9%)	5 (10.0%)	0.526	NA	..
1 or 2 per year	134 (54.5%)	138 (55.9%)	15 (33.3%)	31 (62.0%)	0.090	0.425	..
>2 per year	82 (33.3%)	89 (36.0%)	26 (57.8%)	14 (28.0%)	0.020	0.330	..
Tuberculosis					NA*	NA*	NA*
Ever had and treated	5 (2.0%)	4 (1.6%)	1 (2.2%)	2 (4.0%)
Never had	228 (92.7%)	238 (96.4%)	40 (88.9%)	43 (86.0%)
Does not know	13 (5.3%)	5 (2.0%)	4 (8.9%)	5 (10.0%)
Currently being treated	0	0	0	0
Had heart failure?					0.042	0.113	0.013
No	242 (98.4%)	236 (95.5%)	42 (93.3%)	45 (90.0%)
Yes	4 (1.6%)	11 (4.5%)	3 (6.7%)	5 (10.0%)
Had HIV/AIDS?					NA*	NA*	NA*
No	106 (43.1%)	126 (51.0%)	20 (44.4%)	24 (48.0%)
Yes	8 (3.3%)	14 (5.7%)	2 (4.4%)	3 (6.0%)
Did not know	132 (53.6%)	107 (43.3%)	23 (51.2%)	23 (46.0%)

Data are n (%) or mean (SD). *Too few participants to calculate p value. COPD=chronic obstructive pulmonary disease.

Table 3: Risk factors for COPD

COPD than in participants without COPD (appendix). Heart failure was also significantly associated with COPD (table 3). We detected no significant differences between participants with and without COPD with regards to age, sex, education, tribal origin, asthma, chest infections, living in a tobacco-growing area, type of cooking area, hospital admission in the past 2 years, and health centre visits in the past 2 years. Too few participants had HIV/AIDS or tuberculosis to assess associations for these diseases. We detected a correlation between age and years of exposure to biomass smoke (indoors $r=0.564$, $p<0.0001$ and outdoors $r=0.603$, $p<0.0001$), and age and dyspnoea score ($r=0.291$, $p<0.0001$).

Women were more exposed than were men to biomass smoke, both indoors and outdoors and both in terms of hours per day and number of years (all $p<0.0001$).

Univariate analyses within sexes showed an association with COPD among men with more than two chest infections per year, and a trend among men in villages in tobacco-growing areas (table 3).

Among participants with COPD, 20 (44%) of 45 men and four (8%) of 50 women were current smokers; their mean age was 40.4 years for men and 52.0 years for women (65% of men compared with 5% of women aged 30–39 years were current smokers). 11 (24%) men and nine (18%) women were former smokers; their mean age was 48.6 years and 63.8 years, respectively (figure 3).

Logistic regression analyses showed an association of wheeze and being a former smoker with the presence of COPD; cough, current smoker, heart failure, and hours per day cooking indoors showed trends for association with COPD (table 4).




Figure 3: Smoking status by age and sex for participants with chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease defined as ratio of forced expiratory volume in 1 s to forced vital capacity less than the lower limit of normal.

	Odds ratio (95% CI)	p value
Smoking		
Never smoker	1 (reference)	..
Current smoker	1.669 (0.956–2.914)	0.072
Former smoker	1.960 (1.070–3.589)	0.029
Wheeze		
No	1 (reference)	..
Yes	2.174 (1.088–4.344)	0.028
Cough		
No	1 (reference)	..
Yes	1.625 (0.956–2.761)	0.073
Heart failure		
No	1 (reference)	..
Yes	2.516 (0.979–6.463)	0.055
Time cooking indoors*	1.089 (0.999–1.187)	0.053

See appendix for all results of multivariable analyses. *Hours per day exposed to biomass smoke caused by cooking indoors.

Table 4: Selected results of multivariable analyses for chronic obstructive pulmonary disease

Discussion

FRESH AIR Uganda was one of the first population-based, randomised, cross-sectional surveys done in a rural area of a sub-Saharan country focused on the prevalence and burden of COPD, an unknown disease in the community (panel). The prevalence of spirometry-defined COPD in people older than 30 years was 16%; 39% of them, both men and women, were aged 30–39 years.

Where present, airflow obstruction was not generally severe; the same applied to symptoms, health-related quality of life, and dyspnoea score. The relevance of asymptomatic airflow obstruction in this population is

Panel: Research in context

Systematic review

In 2011, a systematic review was done of the prevalence and effect of asthma and chronic obstructive pulmonary disease (COPD) in sub-Saharan Africa.¹⁰ 119 reports were identified: 32 of asthma, 18 of COPD, 59 of indoor air pollution, and ten of primary care, with some overlap. The limited data showed that the burden of asthma and COPD was rising.^{2,10} These diseases had not been thought of as major health problems. Tobacco smoking was an important risk factor for COPD worldwide, but exposure to biomass fuel could be even greater in sub-Saharan Africa.^{9,10} In 2012, a qualitative survey was done in a rural district of Uganda to explore beliefs and attitudes about respiratory symptoms, use of biomass fuel, tobacco smoking, and use of health services.¹¹ The lack of knowledge (the word “COPD” was totally unknown) created different beliefs and attitudes about respiratory symptoms. Most people used biomass fuels to cook and were unaware of the damage to respiratory health caused by tobacco and biomass smoke.

Interpretation

In our study, the prevalence of spirometry-defined COPD in people older than age 30 years was 16.2%. The prevalence was especially high (39%) in people aged 30–39 years. Whole families are exposed to biomass smoke, mainly caused by wood fires in poorly ventilated cooking areas, starting at early age (even in utero). The high prevalence of COPD, especially in young people, suggests a hidden health problem and the potential for major consequences in the future. Our findings suggest that a major priority should be prevention of exposure by promotion of awareness of the harmful effects of biomass fuel use and tobacco smoke in all communities, and among health-care workers and policy makers.

Environmental toxins caused by biomass fuel, tobacco smoke, kerosene lamps, and occupational exposure should be controlled.⁵ Simple ventilation, including energy-saving stoves and retained-heat cookers, can greatly reduce air pollution. Education is needed for behavioural changes.⁵ Public health and clinical researchers should work together to improve knowledge of early detection, diagnosis, and treatment of COPD and to reduce the present and future burden of chronic lung disease on health systems. These interventions will benefit people at risk of all smoke-attributable morbidity and mortality, not just COPD.

not yet known. However, a fifth of participants with airflow obstruction had two or more exacerbations in the past 12 months.

Almost everybody was exposed to biomass smoke, mainly caused by wood fires in poorly ventilated indoor cooking areas.¹¹ Cigarette smoking was prominent in young men. Young women hardly smoked at all.¹¹ In villages situated among tobacco-growing fields, the leaves were often dried indoors using an open fire and guarded by elderly people and young children.¹¹ Most people—both children and adults—were also exposed to the pollutants

from kerosene-based lighting, an under-rated risk factor for lung damage.^{27,28} We detected a strong correlation between age and the amount of biomass smoke exposure. However, we could not detect a difference in COPD prevalence in relation to biomass exposure because exposure was so common that we lacked a sufficient number of unexposed people to act as a control group. By contrast with results from other large prevalence surveys, often done in urban areas with participants older than 40 years,^{3,6,29} age and sex were not significantly associated with COPD in our survey. A major contributor to these results could be the low average life expectancy in Uganda.

Our study has several limitations. Spirometry was not always done in an ideal environment; nevertheless, the results were evaluated in accordance with American Thoracic Society and European Respiratory Society criteria.⁶ Appropriate spirometry reference values from east Africans did not exist at the time of the survey. We used African and south Indian reference values from 1993.³⁰ In Uganda, as in many countries in Africa, until at least a decade ago, registration births was often incomplete. People often knew their year of birth, but did not know their exact birth date (29% of participants reported being born on Jan 1). The diagnosis of COPD could be difficult in sub-Saharan Africa, where the prevalence of comorbid respiratory infections, such as tuberculosis, is high. However, the prevalence of tuberculosis was low in our study site so we could not detect no association with COPD. Likewise, we could not test for an association between HIV infection and COPD. In rural areas the prevalence of asthma is low compared with urban areas.^{10,31–33} Eight patients with COPD had a change in FEV₁ of more than 12% and 200 mL after a bronchodilator; none of them were known to have asthma.

By contrast with the FEV₁ and FVC, which are affected by race and ethnic origin, the FEV₁:FVC ratio is generally independent of ethnic group and therefore does not require specific reference values.^{23,34} Using GLI2012 DataConversion software, we could define the lower limit of normal for the FEV₁:FVC ratio with reasonable confidence without reference values for FEV₁ and FVC.³⁵ The lower limit of normal as a criterion made possible the identification younger people with an airflow obstruction.

Biomass smoke causes low birthweight and poor lung growth, inducing respiratory infections in early childhood and causing large and lasting effects into adulthood, leading to decline of lung function, and substantially increasing the risk of COPD.^{6–9} Tobacco smoke combined with exposure to smoke from biomass fuel might even have an additive effect on the risk of COPD.^{6,9}

Further research is needed to understand the short-term and long-term effects of these risk factors, and their association in the early development of COPD. Particularly, the progression of airflow obstruction over time needs to be better understood to discover what stage

in life exposure causes most pulmonary damage. A new approach to prevention of lung disease is needed to combine education and support, to reduce exposures, and recognise and diagnose lung diseases at an early stage to minimise their effect. Further research is also needed into affordable and effective interventions for COPD. COPD could be a major health threat to men and women in rural areas of Uganda.

Contributors

FvG, BK, NC, MK, IT, SW, and TvdM designed the survey and organised it in collaboration with JT. FvG, BK, SL, PM, and JT trained the research assistants. FvG, BK, SL, PM, and JT acquired data. FvG, BK, CdJ, RJ, and TvdM analysed and interpreted data. FvG and CdJ did the statistical analysis and prepared the results. FvG wrote the first draft of the report; CdJ, BK, RJ, and TvdM revised the report. All authors gave input to the final version.

Declaration of interests

We declare no competing interests.

Acknowledgments

FRESH AIR Uganda was done by the University Medical Centre Groningen (Netherlands) in close collaboration with Makerere University (Uganda) and the Leiden University Medical Centre (Netherlands). It was funded by the International Primary Care Respiratory Group (UK), supported by an unrestricted grant from Mundipharma International. We thank the staff of the district health office and the health-care workers of Masindi district for making this survey possible. We also thank all the participants.

References

- 1 Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. *Lancet* 2011; **377**: 1438–47.
- 2 WHO. Global surveillance, prevention and control of Chronic Respiratory Diseases: a comprehensive approach. Geneva: World Health Organization, 2007.
- 3 Mannino M, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; **370**: 765–73.
- 4 WHO. World Health Statistics. Geneva: World Health Organization, 2008.
- 5 Forum of International Respiratory Societies. Respiratory diseases in the world: reality of today - opportunities for tomorrow. <http://www.ersnet.org/images/firs-world-report.pdf> (accessed Nov 25, 2014).
- 6 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD, December 2010. www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed Nov 25, 2014).
- 7 Kurmi OP, Lam KB, Ayres JG. Indoor air pollution and the lung in low- and medium-income countries. *Eur Respir J* 2012; **40**: 239–54.
- 8 Perez-Padilla R, Schilmann A, Riojas-Rodriguez H. Respiratory health effects of indoor air pollution. *Int J Tuberc Lung Dis* 2010; **14**: 1079–86.
- 9 Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? *Chest* 2010; **138**: 3–6.
- 10 van Gemert F, van der Molen T, Jones R, Chavannes N. The impact of asthma and COPD in sub-Saharan Africa. *Prim Care Respir J* 2011; **20**: 240–48.
- 11 van Gemert F, Chavannes N, Nabadda N, et al. Impact of chronic respiratory symptoms in a rural area of sub-Saharan Africa: an in-depth qualitative study in the Masindi district of Uganda. *Prim Care Respir J* 2013; **22**: 300–05.
- 12 Finney LJ, Feary JR, Leonardi-Bee J, Gordon SB, Mortimer K. Chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. *Int J Tuberc Lung Dis* 2013; **17**: 583–89.
- 13 Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007; **370**: 741–50.
- 14 Musafiri S, van Meerbeeck J, Musango L, et al. Prevalence of atopy, asthma and COPD in an urban and a rural area of an African country. *Respir Med* 2011; **105**: 1596–605.

- 15 Male-Mukasa JB. Uganda National Household Survey. Uganda Bureau of Statistics. 2010.
- 16 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005; **26**: 319–38.
- 17 Burney PG, Laitinen LA, Perdrizet S, et al. Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. *Eur Respir J* 1989; **2**: 940–45.
- 18 Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. *Respiration* 2006; **73**: 285–95.
- 19 Tinkelman DG, Price DB, Nordyke RJ, et al. Symptom-based questionnaire for differentiating COPD and asthma. *Respiration* 2006; **73**: 296–305.
- 20 Bakke PS, Ronmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD. *Eur Respir J* 2011; **38**: 1261–77.
- 21 Price D, Crockett A, Arne M, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. *Prim Care Respir J* 2009; **18**: 216–23.
- 22 Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005; **26**: 948–68.
- 23 Quanjer PH, Stanojevic S, Cole TJ, et al, and the ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95 year age range: the global lung function 2012 equations. *Eur Respir J* 2012; **40**: 1324–43.
- 24 Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present and future. *Eur Respir J* 2010; **36**: 12–19.
- 25 van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes* 2003; **28**: 13.
- 26 Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. Fourth edn. Blackwell Science, 2002.
- 27 Apple J, Vicente R, Yarberry A, et al. Characterization of particulate matter size distributions and indoor concentrations from kerosene and diesel lamps. *Indoor Air* 2010; **20**: 399–411.
- 28 Lam NL, Smith KR, Gauthier A, Bates MN. Kerosene: a review of household uses and their hazards in low- and middle-income countries. *J Toxicol Environ Health B Crit Rev* 2012; **15**: 396–432.
- 29 Menezes AMB, Perez-Padilla R, Hallal PC, et al. Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. *Int J Tuberc Lung Dis* 2008; **12**: 709–12.
- 30 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J* 1993; **16** (suppl): 5–40.
- 31 Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy* 2004; **59**: 469–78.
- 32 Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax* 2009; **64**: 476–83.
- 33 Wjst M, Boakye D. Asthma in Africa. *PLoS Med* 2007; **4**: e72.
- 34 Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. *Chest* 2011; **139**: 52–59.
- 35 Stocks J, Baur X, Hall G, Culver B. Implementation GLI 2012 regression equations. <http://www.lungfunction.org/files/ImplementingGLIequations.pdf> (accessed Nov 25, 2014).